Please ensure Javascript is enabled for purposes of website accessibility
Eric Volkman

Eric Volkman


Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles.

Recent articles


Why Novavax Stock Tumbled on Thursday

A new authorization from across the ocean fails to impress investors.


Why I'm Never Selling Digital Realty Trust

The company is one of only a few major operators in a very high-potential REIT segment.


Why SmileDirectClub Shot Nearly 5% Higher Today

Investors were heartened by news of a new teeth-whitening product.


Why Bank of America Climbed While the Market Fell Today

The company scored an encouraging beat on the bottom line in its latest reported quarter.


Why Axsome Therapeutics Climbed Today While the Market Fell

The stock receives a positive analyst thumbs-up after it issues a business update.


Why Apple Sank Along With the Stock Market Today

It's not the "A" tech stock investors were clamoring for on the day, plus there was some discouraging legal news for the company.


Why Bed Bath & Beyond Stock Dived by 9% Today

Not for the first time, an influential investment bank has trimmed its price target on the stock.


Is Realty Income's Dividend in Trouble?

The durably popular REIT operates in a sector battered by the pandemic, after all.


Why Marqeta Stock Tumbled More Than 5% Today

Another day, another analyst price-target cut.


Why Peloton Stock Flopped on Friday

The company is getting jettisoned from a prominent stock index.


Why Mirati Therapeutics Was Sinking This Week

A rival to the company's leading pipeline drug wins conditional marketing authorization in a big market abroad.


Why HealthEquity Stock Was Winning Big This Week

The company unveiled some highly encouraging growth statistics.


Why AMC Stock Got Stomped on Thursday

Investors reacted negatively to share sales by two top-level executives.

Man about to receive a vaccine shot

Why Pfizer and BioNTech Got Thrashed on Thursday

A fresh Supreme Court ruling does neither stock any favors.

20 dollar bill

3 Top Stocks You Can Still Buy for Under $20 a Share

Growth stocks have fallen out of favor, which provides a juicy opportunity to snap up this trio of beauties.

Medical professional storing swab sample

Why Quest Diagnostics Fell Nearly 7% Today

The company's preliminary Q4 results topped analyst expectations, but investors were likely expecting better performance.

Gloved hand filling a syringe from a vial

Why Ocugen Stock Couldn't Outrun the Market Today

The coronavirus vaccine that it has licensed does very well against variants like omicron, but it's still a laggard.

Cannabis flower in a bowl on top of US currency

Down 15%, Is Innovative Industrial Properties a Buy?

The company is by far the most significant REIT specializing in the marijuana industry.


Why Veru Stock Triumphed on Tuesday

The company wins Fast Track designation for a top pipeline program.

Beyond Meat Italian Sausage

Why Beyond Meat Stock Shot 4% Higher Today

It was all about Canadians and pizza.